Il rapporto
Notizie verificate su finanziamenti, sedi centrali e leadership delle aziende più innovative al mondo
198 report e oltre
AusperBio Raises $120M Series C for Hepatitis B Oligonucleotide Therapies
AusperBio closed a $120 million Series C led by a strategic investor, with new investor RA Capital participating, to advance its hepatitis B candidate AHB-137.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Kailera Therapeutics raises $400M in Series A at $1.5B valuation. Developing obesity therapeutics with acquired pipeline...
Expedition Therapeutics raises $165M Series B at $850M valuation
Expedition Therapeutics raises $165M in Series B at $850M valuation. Developing novel therapeutics for cardiometabolic diseases...
Candid Therapeutics raises $370M Series A at $1.2B valuation
Candid Therapeutics raises $370M in Series A at $1.2B valuation. Developing novel therapeutics for autoimmune diseases...
Visualizzazione di 9 report • Pagina 1 • Categoria: all
Rimani avanti rispetto al mercato
Ricevi insight settimanali nella tua casella di posta. Niente spam, solo intelligenza.